{"success":true,"data":{"pressRelease":{"id":"159780","rtpr_id":"nPnbLfq6Ja-20261002","ticker":"IART","exchange":"NASDAQ","all_tickers":["IART"],"title":"Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)","author":"PR Newswire","published_at":"2026-10-02T22:42:00.039Z","article_body":"Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)\nPR Newswire\n\nNEW YORK, Oct. 2, 2026\n\nA $4.3 million to $6.3 million gap between Integra's preliminary third-quarter\nrevenue and the Wall Street estimate sent IART shares lower. SueWallSt\nnotifies investors of a pending investigation into potential securities claims\nfor shareholders who lost money.\n\nNEW YORK, Oct. 2, 2026 /PRNewswire/ -- Integra LifeSciences (NASDAQ: IART)\nshares fell sharply on October 2, 2026, after the Company put preliminary\nthird-quarter revenue at $410 million to $412 million -- short of the $416.3\nmillion FactSet consensus estimate. Investors who bought IART and are now\nholding losses may have legal rights. Affected shareholders are encouraged to\nsubmit their IART loss details now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4788852-1&h=3535231219&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fintegra-lifesciences-holdings-corporation-investigation-iart%3Fprid%3D210466%26wire%3D4&a=submit+their+IART+loss+details+now)\n or contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or by telephone at (888) SueWallSt.\n\nIntegra further cut its full year revenue, \"from a range of $1.654 billion to\n$1.695 billion to a range of $1.634 billion to $1.654 billion.\" The Company\nblamed the shortfall on \"flooding at the Cincinnati facility in July 2026,\"\nnoting the \"disruption negatively impacted third quarter revenue by\napproximately $7 million,\" and a projected further negative impact of $15 to\n$20 million to fourth quarter revenue. The Company further disclosed it now\ndoes not see a return to full manufacturing operations until the second\nquarter of 2027.\n\nDuring Integra's previous earnings call on July 29, 2026, Chief Financial\nOfficer Lea Daniels Knight discussed the Cincinnati facility flooding incident\nbriefly, informing investors the Company did \"not expect the event to have a\nmaterial impact on our revenue or EPS guidance for 2026.\"\n\nInvestors who suffered losses on Integra LifeSciences shares can start a free\nreview of their IART losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4788852-1&h=2955011286&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fintegra-lifesciences-holdings-corporation-investigation-iart%3Fprid%3D210466%26wire%3D4&a=start+a+free+review+of+their+IART+losses)\n while the investigation is active, or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the IART Investigation\n\nQ: How much did IART stock drop?A: Shares opened down $2.79 per share, or\nabout 17% on October 2, 2026. By midday the stock had fallen further to a near\n20%. Investors who purchased shares at allegedly inflated prices and suffered\nlosses may be eligible to seek compensation.\n\nQ: Which statements are being investigated as potentially misleading?A: The\ninvestigation concerns whether statements Integra LifeSciences made about its\nmanufacturing operations and projected results may have been misleading. When\nthe Company disclosed surprise revenue impacts from a flooding event\nmanagement previously characters as not expected to \"have a material impact\"\non revenue or earnings, the stock price declined sharply.\n\nQ: When did Integra LifeSciences allegedly mislead investors?A: The\ninvestigation concerns statements made before the October 2, 2026 disclosure\nthat may have caused investors to purchase IART securities at inflated prices.\n\nQ: What do IART investors need to do right now?A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4788852-1&h=2972383777&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fintegra-lifesciences-holdings-corporation-investigation-iart%3Fprid%3D210466%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible to participate in the\ninvestigation.\n\nQ: What documents do I need to participate?A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: What if I already sold my IART shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought IART and sold at a loss may still participate in\nthe investigation.\n\nQ: Do I need to go to court or give testimony?A: No. Participating in the\ninvestigation does not require court appearances or depositions. If legal\naction is later pursued, the overwhelming majority of affected investors never\nappear in court either.\n\nQ: What does it cost me to participate?A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in any resulting action, these matters are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/integra-lifesciences-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-integra-lifesciences-iart-302897459.html\n(https://www.prnewswire.com/news-releases/integra-lifesciences-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-integra-lifesciences-iart-302897459.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2985247\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbLfq6Ja-20261002","title":"Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)","author":"PR Newswire","ticker":"IART","created":"2026-10-02T22:42:00.039Z","tickers":["IART"],"exchange":"NASDAQ","article_body":"Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)\nPR Newswire\n\nNEW YORK, Oct. 2, 2026\n\nA $4.3 million to $6.3 million gap between Integra's preliminary third-quarter\nrevenue and the Wall Street estimate sent IART shares lower. SueWallSt\nnotifies investors of a pending investigation into potential securities claims\nfor shareholders who lost money.\n\nNEW YORK, Oct. 2, 2026 /PRNewswire/ -- Integra LifeSciences (NASDAQ: IART)\nshares fell sharply on October 2, 2026, after the Company put preliminary\nthird-quarter revenue at $410 million to $412 million -- short of the $416.3\nmillion FactSet consensus estimate. Investors who bought IART and are now\nholding losses may have legal rights. Affected shareholders are encouraged to\nsubmit their IART loss details now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4788852-1&h=3535231219&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fintegra-lifesciences-holdings-corporation-investigation-iart%3Fprid%3D210466%26wire%3D4&a=submit+their+IART+loss+details+now)\n or contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or by telephone at (888) SueWallSt.\n\nIntegra further cut its full year revenue, \"from a range of $1.654 billion to\n$1.695 billion to a range of $1.634 billion to $1.654 billion.\" The Company\nblamed the shortfall on \"flooding at the Cincinnati facility in July 2026,\"\nnoting the \"disruption negatively impacted third quarter revenue by\napproximately $7 million,\" and a projected further negative impact of $15 to\n$20 million to fourth quarter revenue. The Company further disclosed it now\ndoes not see a return to full manufacturing operations until the second\nquarter of 2027.\n\nDuring Integra's previous earnings call on July 29, 2026, Chief Financial\nOfficer Lea Daniels Knight discussed the Cincinnati facility flooding incident\nbriefly, informing investors the Company did \"not expect the event to have a\nmaterial impact on our revenue or EPS guidance for 2026.\"\n\nInvestors who suffered losses on Integra LifeSciences shares can start a free\nreview of their IART losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4788852-1&h=2955011286&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fintegra-lifesciences-holdings-corporation-investigation-iart%3Fprid%3D210466%26wire%3D4&a=start+a+free+review+of+their+IART+losses)\n while the investigation is active, or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the IART Investigation\n\nQ: How much did IART stock drop?A: Shares opened down $2.79 per share, or\nabout 17% on October 2, 2026. By midday the stock had fallen further to a near\n20%. Investors who purchased shares at allegedly inflated prices and suffered\nlosses may be eligible to seek compensation.\n\nQ: Which statements are being investigated as potentially misleading?A: The\ninvestigation concerns whether statements Integra LifeSciences made about its\nmanufacturing operations and projected results may have been misleading. When\nthe Company disclosed surprise revenue impacts from a flooding event\nmanagement previously characters as not expected to \"have a material impact\"\non revenue or earnings, the stock price declined sharply.\n\nQ: When did Integra LifeSciences allegedly mislead investors?A: The\ninvestigation concerns statements made before the October 2, 2026 disclosure\nthat may have caused investors to purchase IART securities at inflated prices.\n\nQ: What do IART investors need to do right now?A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nSubmit your information for a no-cost, no-obligation evaluation of your\npotential recovery\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4788852-1&h=2972383777&u=https%3A%2F%2Fsuewallst.com%2Finvestigations%2Fintegra-lifesciences-holdings-corporation-investigation-iart%3Fprid%3D210466%26wire%3D4&a=Submit+your+information+for+a+no-cost%2C+no-obligation+evaluation+of+your+potential+recovery)\n. No immediate action is required to remain eligible to participate in the\ninvestigation.\n\nQ: What documents do I need to participate?A: Brokerage statements or trade\nconfirmations showing purchase dates, share quantities, prices paid, and any\nsubsequent sale dates and prices.\n\nQ: What if I already sold my IART shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought IART and sold at a loss may still participate in\nthe investigation.\n\nQ: Do I need to go to court or give testimony?A: No. Participating in the\ninvestigation does not require court appearances or depositions. If legal\naction is later pursued, the overwhelming majority of affected investors never\nappear in court either.\n\nQ: What does it cost me to participate?A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in any resulting action, these matters are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/integra-lifesciences-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-integra-lifesciences-iart-302897459.html\n(https://www.prnewswire.com/news-releases/integra-lifesciences-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-integra-lifesciences-iart-302897459.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2985247\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-02T22:42:00.133235076Z","server_sent_at_ms":1790980920133},"received_at":"2026-10-02T22:42:00.184Z","source_url":"https://www.prnewswire.com/news-releases/integra-lifesciences-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-integra-lifesciences-iart-302897459.html"},"analysis":{"id":"148363","press_release_id":"159780","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["issuer previously said Cincinnati flooding would not have a material impact on 2026 revenue or EPS","full manufacturing operations not expected until Q2 2027"],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky, announced a pending investigation into potential securities claims against Integra LifeSciences (IART) following the October 2 revenue disclosure.\n\nThe trigger: preliminary Q3 revenue of $410-412 million missed the $416.3 million FactSet consensus, FY guidance was cut, and the stock fell roughly 17-20%.\n\nThis is a law-firm solicitation seeking loss submissions, not a new issuer disclosure or court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; underlying guidance cut already captured elsewhere."},"keyFigures":{"guidance":"FY revenue guidance cut from $1.654B-$1.695B to $1.634B-$1.654B","customDimensions":{"stock_drop":"opened down about 17%, fell to near 20% by midday","factset_consensus_estimate":"$416.3 million","q3_flooding_revenue_impact":"approximately $7 million","preliminary_q3_revenue_range":"$410 million to $412 million","q4_projected_flooding_impact":"$15 to $20 million"}},"quotedText":"from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky LLP"},{"name":"Lea Daniels Knight","role":"CFO"}],"products":[],"companies":[{"name":"Integra LifeSciences","ticker":"IART","relationship":"investigation target"},{"name":"SueWallSt / Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$410 million to $412 million","context":"preliminary Q3 revenue"},{"amount":"$416.3 million","context":"FactSet consensus estimate"},{"amount":"$1.654 billion to $1.695 billion","context":"prior FY revenue guidance"},{"amount":"$1.634 billion to $1.654 billion","context":"revised FY revenue guidance"},{"amount":"$7 million","context":"Q3 revenue impact from Cincinnati facility flooding"},{"amount":"$15 to $20 million","context":"projected Q4 revenue impact from flooding"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff-firm (SueWallSt/Levi & Korsinsky) solicitation seeking IART loss submissions. No new issuer disclosure, no certified class, no settlement; the underlying revenue miss is context, not new information from the company."},"tickerRelevance":{"others":[],"primary":"IART"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky, announced a pending investigation into potential securities claims against Integra LifeSciences (IART) following the October 2 revenue disclosure.\n\nThe trigger: preliminary Q3 revenue of $410-412 million missed the $416.3 million FactSet consensus, FY guidance was cut, and the stock fell roughly 17-20%.\n\nThis is a law-firm solicitation seeking loss submissions, not a new issuer disclosure or court action; treat as low-signal noise.","key_figures":{"guidance":"FY revenue guidance cut from $1.654B-$1.695B to $1.634B-$1.654B","customDimensions":{"stock_drop":"opened down about 17%, fell to near 20% by midday","factset_consensus_estimate":"$416.3 million","q3_flooding_revenue_impact":"approximately $7 million","preliminary_q3_revenue_range":"$410 million to $412 million","q4_projected_flooding_impact":"$15 to $20 million"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky LLP"},{"name":"Lea Daniels Knight","role":"CFO"}],"products":[],"companies":[{"name":"Integra LifeSciences","ticker":"IART","relationship":"investigation target"},{"name":"SueWallSt / Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$410 million to $412 million","context":"preliminary Q3 revenue"},{"amount":"$416.3 million","context":"FactSet consensus estimate"},{"amount":"$1.654 billion to $1.695 billion","context":"prior FY revenue guidance"},{"amount":"$1.634 billion to $1.654 billion","context":"revised FY revenue guidance"},{"amount":"$7 million","context":"Q3 revenue impact from Cincinnati facility flooding"},{"amount":"$15 to $20 million","context":"projected Q4 revenue impact from flooding"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T22:42:16.465Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small/mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":16260,"modelName":"glm-5.3-flashx"}}